Source comparison
TB-500 vs Other Tendon Injury Treatments
TB-500 (2.5mg 2x/week) Promotes collagen synthesis, enhances cell migration, upregulates angiogenesis 6–12 weeks Preclinical strong; human case series only Biologically plausible adjunct; requires concurrent load management BPC-157 (250–500mcg daily) Enhances
This comparison does not assign a generated winner or score.
- TB-500 (2.5mg 2x/week)
- Promotes collagen synthesis, enhances cell migration, upregulates angiogenesis
- 6–12 weeks
- Preclinical strong; human case series only
- Biologically plausible adjunct; requires concurrent load management
- BPC-157 (250–500mcg daily)
- Enhances fibroblast activity, promotes VEGF expression, modulates growth hormone receptor
- 4–8 weeks
- Preclinical moderate; no human RCTs
- Often stacked with TB-500; overlapping mechanisms suggest potential synergy
- Eccentric wrist extension exercise
- Mechanically remodels tendon structure through controlled loading
- 8–16 weeks
- High (multiple RCTs)
- Gold standard conservative treatment; non-negotiable foundation
- Corticosteroid injection
- Suppresses inflammation; provides short-term pain relief
- 1–4 weeks (temporary)
- High for short-term pain; harmful long-term
- Weakens tendon structure; avoid in chronic tendinosis
- Platelet-Rich Plasma (PRP)
- Delivers growth factors (PDGF, TGF-β) to injury site
- Moderate (mixed RCT results)
- More invasive than peptides; insurance rarely covers